Lidocaine (Xylocaine) as an anti-arrhythmic agent.
D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D004562:Electrocardiography; D006329:Heart Conduction System / Q000503:physiopathology; D006352:Heart Ventricles; D006801:Humans; D007275:Injections, Intravenous; D008012:Lidocaine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008991:Monitoring, Physiologic; D009203:Myocardial Infarction; D010292:Paresthesia / Q000139:chemically induced; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D012640:Seizures / Q000139:chemically induced; D013610:Tachycardia / Q000188:drug therapy; D014012:Tinnitus / Q000139:chemically induced; D014693:Ventricular Fibrillation / Q000188:drug therapy; D014717:Vertigo / Q000139:chemically induced; D014786:Vision Disorders / Q000139:chemically induced
D000889:Anti-Arrhythmia Agents; D008012:Lidocaine; D011802:Quinidine; D011342:Procainamide